QQQ   359.44 (+0.33%)
AAPL   173.33 (+1.24%)
MSFT   318.77 (+0.96%)
META   304.19 (+1.33%)
GOOGL   133.25 (+1.83%)
AMZN   128.95 (+1.44%)
TSLA   252.39 (+0.87%)
NVDA   446.39 (+2.62%)
NIO   8.81 (-2.54%)
BABA   86.07 (-0.77%)
AMD   102.71 (-0.11%)
T   14.79 (-1.53%)
F   12.30 (-0.97%)
MU   67.41 (-0.91%)
CGC   0.76 (-3.46%)
GE   108.29 (-2.04%)
DIS   80.95 (-0.12%)
AMC   7.93 (-0.75%)
PFE   33.38 (+0.63%)
PYPL   58.16 (-0.51%)
NFLX   379.44 (+0.49%)
QQQ   359.44 (+0.33%)
AAPL   173.33 (+1.24%)
MSFT   318.77 (+0.96%)
META   304.19 (+1.33%)
GOOGL   133.25 (+1.83%)
AMZN   128.95 (+1.44%)
TSLA   252.39 (+0.87%)
NVDA   446.39 (+2.62%)
NIO   8.81 (-2.54%)
BABA   86.07 (-0.77%)
AMD   102.71 (-0.11%)
T   14.79 (-1.53%)
F   12.30 (-0.97%)
MU   67.41 (-0.91%)
CGC   0.76 (-3.46%)
GE   108.29 (-2.04%)
DIS   80.95 (-0.12%)
AMC   7.93 (-0.75%)
PFE   33.38 (+0.63%)
PYPL   58.16 (-0.51%)
NFLX   379.44 (+0.49%)
QQQ   359.44 (+0.33%)
AAPL   173.33 (+1.24%)
MSFT   318.77 (+0.96%)
META   304.19 (+1.33%)
GOOGL   133.25 (+1.83%)
AMZN   128.95 (+1.44%)
TSLA   252.39 (+0.87%)
NVDA   446.39 (+2.62%)
NIO   8.81 (-2.54%)
BABA   86.07 (-0.77%)
AMD   102.71 (-0.11%)
T   14.79 (-1.53%)
F   12.30 (-0.97%)
MU   67.41 (-0.91%)
CGC   0.76 (-3.46%)
GE   108.29 (-2.04%)
DIS   80.95 (-0.12%)
AMC   7.93 (-0.75%)
PFE   33.38 (+0.63%)
PYPL   58.16 (-0.51%)
NFLX   379.44 (+0.49%)
QQQ   359.44 (+0.33%)
AAPL   173.33 (+1.24%)
MSFT   318.77 (+0.96%)
META   304.19 (+1.33%)
GOOGL   133.25 (+1.83%)
AMZN   128.95 (+1.44%)
TSLA   252.39 (+0.87%)
NVDA   446.39 (+2.62%)
NIO   8.81 (-2.54%)
BABA   86.07 (-0.77%)
AMD   102.71 (-0.11%)
T   14.79 (-1.53%)
F   12.30 (-0.97%)
MU   67.41 (-0.91%)
CGC   0.76 (-3.46%)
GE   108.29 (-2.04%)
DIS   80.95 (-0.12%)
AMC   7.93 (-0.75%)
PFE   33.38 (+0.63%)
PYPL   58.16 (-0.51%)
NFLX   379.44 (+0.49%)
Followed 132 TimesTop Followed
NYSE:ABBV

AbbVie (ABBV) Stock Forecast, Price & News

$147.01
-2.05 (-1.38%)
(As of 12:52 PM ET)
Compare
Today's Range
$146.86
▼
$148.86
50-Day Range
$141.63
▼
$154.70
52-Week Range
$130.96
▼
$168.11
Volume
1.50 million shs
Average Volume
5.56 million shs
Market Capitalization
$259.48 billion
P/E Ratio
30.25
Dividend Yield
4.03%
Price Target
$166.53
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

AbbVie MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
12.2% Upside
$166.53 Price Target
Short Interest
Healthy
0.68% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.42mentions of AbbVie in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$2.76 M Sold Last Quarter
Proj. Earnings Growth
-0.09%
From $11.03 to $11.02 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.93 out of 5 stars

Medical Sector

42nd out of 969 stocks

Pharmaceutical Preparations Industry

10th out of 453 stocks

See Top Rated MarketRank™ Stocks Here

ABBV stock logo

About AbbVie (NYSE:ABBV) Stock

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Price History

ABBV Stock News Headlines

September 26, 2023 | marketbeat.com
Clorox Pullback Presents a Chance to Clean Up on a 3.6% Dividend (ABBV)
The Clorox Company's 44% two-year plunge has created an opportunity to own a defensive stock with a shiny 3.6% dividend.
September 25, 2023 | marketbeat.com
This Proven 200% Dividend Growth Strategy Is a Peter Lynch Favorite
October 2, 2023 | PressReach (Ad)
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
September 25, 2023 | marketbeat.com
Argenx's 28% Surge & Promising Product Propel Investor Confidence (ABBV)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
September 20, 2023 | marketbeat.com
Flee to Healthcare Stocks if Recession Rears its Head? (ABBV)
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.
September 12, 2023 | marketbeat.com
High Yield, Low Beta Stocks to Buy for the Next Market Meltdown (ABBV)
The market is set up for a fall, and it may start soon, as soon as the CPI data is released. These low-beta stocks are poised to outperform and pay dividends
September 30, 2023 | msn.com
UPDATE 2-AbbVie's blood cancer combo therapy fails in late-stage study
September 30, 2023 | americanbankingnews.com
AbbVie (NYSE:ABBV) Now Covered by Raymond James
October 2, 2023 | PressReach (Ad)
Nuclear Revival Creates Opportunities for Uranium
Uranium companies set to benefit from increased demand for clean energy.
September 29, 2023 | markets.businessinsider.com
What 4 Analyst Ratings Have To Say About AbbVie
September 29, 2023 | seekingalpha.com
Ionis, AbbVie, Alnylam draw bullish views at Raymond James
September 29, 2023 | msn.com
AbbVie's Leukemia Drug Falls Short In Late-Stage Study In Pretreated Blood Cancer Patients
September 29, 2023 | markets.businessinsider.com
AbbVie's Promising Leap Towards Long-Term Growth: Analyst
September 29, 2023 | markets.businessinsider.com
AbbVie Says Phase 3 CANOVA Trial Fails To Meet Primary Endpoint
September 29, 2023 | marketwatch.com
AbbVie: Phase 3 Venetoclax/Dexamethasone Study Falls Short in Multiple Myeloma
September 29, 2023 | reuters.com
AbbVie's blood cancer combo therapy fails in late-stage study
September 29, 2023 | msn.com
AbbVie blood cancer therapy fails in Phase 3 trial
September 29, 2023 | finance.yahoo.com
AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
September 29, 2023 | finance.yahoo.com
UPDATE 1-AbbVie's blood cancer combo therapy fails in late-stage study
September 29, 2023 | finance.yahoo.com
Dividend Aristocrats Ranked By Yield: Top 25
September 28, 2023 | finance.yahoo.com
Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?
September 28, 2023 | finance.yahoo.com
Top Analyst Reports for Oracle, AbbVie & Lowe's
September 26, 2023 | finance.yahoo.com
AbbVie Inc.'s (NYSE:ABBV) Intrinsic Value Is Potentially 57% Above Its Share Price
September 26, 2023 | msn.com
AbbVie opens European services hub in Dublin
September 25, 2023 | benzinga.com
How Is The Market Feeling About AbbVie?
September 25, 2023 | marketwatch.com
AbbVie, Genmab Get Conditional Europe OK of Tepkinly Lymphoma Drug
September 25, 2023 | markets.businessinsider.com
AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R Diffuse Large B-cell Lymphoma
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

ABBV Company Calendar

Ex-Dividend for 8/15 Dividend
7/13/2023
Last Earnings
7/27/2023
Dividend Payable
8/15/2023
Today
10/02/2023
Ex-Dividend for 11/15 Dividend
10/12/2023
Next Earnings (Estimated)
10/27/2023
Dividend Payable
11/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NYSE:ABBV
CUSIP
00287Y10
CIK
1551152
Web
www.abbvie.com
Phone
(847) 932-7900
Fax
302-655-5049
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Forecast
$166.53
High Stock Price Forecast
$195.00
Low Stock Price Forecast
$140.00
Forecasted Upside/Downside
+11.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
16 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$4.86
Trailing P/E Ratio
30.67
Forward P/E Ratio
13.51
P/E Growth
2.7
Net Income
$11.84 billion
Net Margins
15.50%
Pretax Margin
18.65%
Return on Equity
151.29%
Return on Assets
16.37%

Debt

Debt-to-Equity Ratio
4.33
Current Ratio
0.89
Quick Ratio
0.77

Sales & Book Value

Annual Sales
$58.05 billion
Price / Sales
4.53
Cash Flow
$18.70 per share
Price / Cash Flow
7.97
Book Value
$9.78 per share
Price / Book
15.24

Miscellaneous

Outstanding Shares
1,765,050,000
Free Float
1,760,458,000
Market Cap
$263.10 billion
Optionable
Optionable
Beta
0.58

Social Links

Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Richard A. GonzalezMr. Richard A. Gonzalez (Age 69)
    Chairman & CEO
    Comp: $6.95M
  • Mr. Robert A. MichaelMr. Robert A. Michael (Age 53)
    Pres & COO
    Comp: $4M
  • Mr. Scott T. ReentsMr. Scott T. Reents (Age 55)
    Exec. VP & CFO
    Comp: $2.97M
  • Dr. Azita Saleki-Gerhardt Ph.D.Dr. Azita Saleki-Gerhardt Ph.D. (Age 60)
    Exec. VP & COO
    Comp: $2.58M
  • Mr. Jeffrey Ryan StewartMr. Jeffrey Ryan Stewart (Age 54)
    Exec. VP & Chief Commercial Officer
    Comp: $2.98M
  • Dr. Thomas J. Hudson M.D. (Age 61)
    Sr. VP of R&D and Chief Scientific Officer
  • Ms. Elizabeth Shea
    VP of Investor Relations
  • Ms. Tracie Haas
    Sr. VP of Corp. Responsibility, Brand & Communications
  • Mr. Timothy J. RichmondMr. Timothy J. Richmond (Age 57)
    Exec. VP & Chief HR Officer
  • Dr. Nicholas R. Donoghoe M.D. (Age 42)
    Exec. VP and Chief Bus. & Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ABBV Stock - Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABBV shares.
View ABBV analyst ratings or view top-rated stocks.

What is AbbVie's stock price forecast for 2023?

16 Wall Street research analysts have issued twelve-month price targets for AbbVie's shares. Their ABBV share price forecasts range from $140.00 to $195.00. On average, they expect the company's share price to reach $166.53 in the next year. This suggests a possible upside of 11.7% from the stock's current price.
View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts.

How have ABBV shares performed in 2023?

AbbVie's stock was trading at $161.61 on January 1st, 2023. Since then, ABBV shares have decreased by 7.8% and is now trading at $149.06.
View the best growth stocks for 2023 here.

Are investors shorting AbbVie?

AbbVie saw a drop in short interest during the month of August. As of August 31st, there was short interest totaling 12,450,000 shares, a drop of 6.1% from the August 15th total of 13,260,000 shares. Based on an average daily trading volume, of 5,160,000 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.7% of the shares of the stock are short sold.
View AbbVie's Short Interest.

When is AbbVie's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our ABBV earnings forecast.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) posted its earnings results on Thursday, July, 27th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.79 by $0.12. The business had revenue of $13.87 billion for the quarter, compared to analyst estimates of $13.52 billion. AbbVie had a net margin of 15.50% and a trailing twelve-month return on equity of 151.29%.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, September 8th. Shareholders of record on Friday, October 13th will be paid a dividend of $1.48 per share on Wednesday, November 15th. This represents a $5.92 annualized dividend and a yield of 3.97%. The ex-dividend date of this dividend is Thursday, October 12th.
Read our dividend analysis for ABBV.

What ETFs hold AbbVie's stock?

ETFs with the largest weight of AbbVie (NYSE:ABBV) stock in their portfolio include First Trust Morningstar Dividend Leaders Index (FDL), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Horizon Kinetics Medical ETF (MEDX), iShares Core High Dividend ETF (HDV), Invesco Pharmaceuticals ETF (PJP), Simplify Health Care ETF (PINK), Health Care Select Sector SPDR Fund (XLV) and VanEck Pharmaceutical ETF (PPH).

Is AbbVie a good dividend stock?

AbbVie (NYSE:ABBV) pays an annual dividend of $5.92 per share and currently has a dividend yield of 3.97%. ABBV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 121.81%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ABBV will have a dividend payout ratio of 53.72% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for ABBV.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its third quarter 2023 earnings guidance on Friday, July, 28th. The company provided earnings per share guidance of $2.80-$2.90 for the period, compared to the consensus EPS estimate of $2.82. The company issued revenue guidance of $13.70 billion-$13.70 billion, compared to the consensus revenue estimate of $13.35 billion.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Rogers Communications (RCI) and Open Text (OTEX).

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $149.06.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $263.10 billion and generates $58.05 billion in revenue each year. The company earns $11.84 billion in net income (profit) each year or $4.86 on an earnings per share basis.

How many employees does AbbVie have?

The company employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?
The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More
How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for the company is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -